LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results for the quarter ended June 30, 2007.
The Company reported a net loss of $16.7 million for the second quarter ended June 30, 2007, compared to a net loss of $14.6 million for the same quarter ended June 30, 2006. Cash, cash equivalents and marketable securities at June 30, 2007 were $64.5 million.
